Peptides and peptidomimetics as therapeutic agents for Covid‐19
Abstract The severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) Covid‐19 pandemic has caused high morbidity and mortality rates worldwide. Virus entry into cells can be blocked using several strategies, including inhibition of protein‐protein interactions (PPIs) between the viral spike glycoprotein and cellular receptors, as well as blocking of spike protein conformational changes that are required for cleavage/activation and fusogenicity. The spike‐mediated viral attachment and entry into cells via fusion of the viral envelope with cellular membranes involve PPIs mediated by short peptide fragments exhibiting particular secondary structures. Thus, peptides that can inhibit these PPIs may be used as potential antiviral agents preventing virus entry and spread. This review is focused on peptides and peptidomimetics as PPI modulators and protease inhibitors against SARS‐CoV‐2..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:114 |
|---|---|
| Enthalten in: |
Peptide Science - 114(2022), 1 |
| Beteiligte Personen: |
Dahal, Achyut [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 Wiley Periodicals LLC. |
|---|
| Umfang: |
16 |
|---|
| doi: |
10.1002/pep2.24245 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY012257117 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY012257117 | ||
| 003 | DE-627 | ||
| 005 | 20230307235410.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230219s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/pep2.24245 |2 doi | |
| 028 | 5 | 2 | |a PEP2_PEP224245.xml |
| 035 | |a (DE-627)WLY012257117 | ||
| 035 | |a (WILEY)PEP224245 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 570 |a 540 |q ASE |
| 084 | |a 35.76 |2 bkl | ||
| 100 | 1 | |a Dahal, Achyut |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Peptides and peptidomimetics as therapeutic agents for Covid‐19 |
| 264 | 1 | |c 2022 | |
| 300 | |a 16 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 Wiley Periodicals LLC. | ||
| 520 | |a Abstract The severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) Covid‐19 pandemic has caused high morbidity and mortality rates worldwide. Virus entry into cells can be blocked using several strategies, including inhibition of protein‐protein interactions (PPIs) between the viral spike glycoprotein and cellular receptors, as well as blocking of spike protein conformational changes that are required for cleavage/activation and fusogenicity. The spike‐mediated viral attachment and entry into cells via fusion of the viral envelope with cellular membranes involve PPIs mediated by short peptide fragments exhibiting particular secondary structures. Thus, peptides that can inhibit these PPIs may be used as potential antiviral agents preventing virus entry and spread. This review is focused on peptides and peptidomimetics as PPI modulators and protease inhibitors against SARS‐CoV‐2. | ||
| 700 | 1 | |a Sonju, Jafrin Jobayer |4 aut | |
| 700 | 1 | |a Kousoulas, Konstantin G. |4 aut | |
| 700 | 1 | |a Jois, Seetharama D. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Peptide Science |g 114(2022), 1 |w (DE-627)WLY012255629 |x 24758817 |7 nnns |
| 773 | 1 | 8 | |g volume:114 |g year:2022 |g number:1 |g extent:16 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 35.76 |q ASE |
| 951 | |a AR | ||
| 952 | |d 114 |j 2022 |e 1 |g 16 | ||